Paroxysmal nocturnal hemoglobinuria: where are we going
AG Kulasekararaj, I Lazana - American journal of hematology, 2023 - Wiley Online Library
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare nonmalignant clonal hematological
disorder that is characterized by a deficiency of the GPI‐linked complement regulators on …
disorder that is characterized by a deficiency of the GPI‐linked complement regulators on …
Paroxysmal nocturnal hemoglobinuria: current management, unmet needs, and recommendations
M Oliver, CJ Patriquin - Journal of Blood Medicine, 2023 - Taylor & Francis
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare, acquired clonal abnormality,
which renders hematopoietic cells exquisitely sensitive to complement-mediated …
which renders hematopoietic cells exquisitely sensitive to complement-mediated …
[HTML][HTML] Comparative effectiveness of pegcetacoplan versus ravulizumab and eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal …
R Wong, J Fishman, K Wilson, M Yeh, M Al-Adhami… - Advances in …, 2023 - Springer
Introduction In the absence of head-to-head trials, this study compared treatment outcomes
with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor …
with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor …
[HTML][HTML] AstraZeneca ADR Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in …
T Avanza - Change - placera.se
Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA
Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy …
Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy …
[HTML][HTML] oydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic …
B Yadav - pharmashots.com
Voydeya (danicopan) has been recommended for marketing authorisation in the European
Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients …
Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients …
[HTML][HTML] AstraZeneca: Long-term ALPHA Phase III trial data showed danicopan as add-on to Ultomiris or Soliris sustained clinical improvements in subset of patients …
D Mode - mfn.se
Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA
Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy Ultomiris …
Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy Ultomiris …
[PDF][PDF] KEY AREAS OF CONCERN
TL Square - Institute for Clinical and Economic Review, 2024 - icer.org
ICER assumes that the ravulizumab BTH rate is 17.14% in Table 4.5, p. 23 of the draft
evidence report. This figure comes from the C5 inhibitor arm of the APPLY-PNH trial. As …
evidence report. This figure comes from the C5 inhibitor arm of the APPLY-PNH trial. As …
[HTML][HTML] Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic …
T Avanza - placera.se
Voydeya (danicopan) has been recommended for marketing authorisation in the European
Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients …
Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients …
[HTML][HTML] Long-term ALPHA Phase III trial data showed danicopan as add-on to Ultomiris or Soliris sustained clinical improvements in subset of patients with PNH …
T Avanza - placera.se
Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA
Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy Ultomiris …
Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy Ultomiris …
[HTML][HTML] Voydeya recommended for EU approval
AG Renk - sharecast.com
Voydeya (danicopan) has been recommended for marketing authorisation in the European
Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients …
Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients …